- Home
- KAVL vs AWH Comparison
KAVL vs AWH Comparison
Compare KAVL & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- AWH
- Stock Information
- Founded
- KAVL 1998
- AWH 1993
- Country
- KAVL United States
- AWH United States
- Employees
- KAVL N/A
- AWH N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- AWH Medical/Dental Instruments
- Sector
- KAVL Health Care
- AWH Health Care
- Exchange
- KAVL Nasdaq
- AWH Nasdaq
- Market Cap
- KAVL 8.9M
- AWH 10.5M
- IPO Year
- KAVL N/A
- AWH N/A
- Fundamental
- Price
- KAVL $1.18
- AWH $0.44
- Analyst Decision
- KAVL
- AWH Buy
- Analyst Count
- KAVL 0
- AWH 2
- Target Price
- KAVL N/A
- AWH $4.40
- AVG Volume (30 Days)
- KAVL 1.1M
- AWH 93.3K
- Earning Date
- KAVL 02-13-2025
- AWH 11-14-2024
- Dividend Yield
- KAVL N/A
- AWH N/A
- EPS Growth
- KAVL N/A
- AWH N/A
- EPS
- KAVL N/A
- AWH N/A
- Revenue
- KAVL $10,108,906.00
- AWH $8,963,000.00
- Revenue This Year
- KAVL $652.90
- AWH $11.87
- Revenue Next Year
- KAVL N/A
- AWH $79.10
- P/E Ratio
- KAVL N/A
- AWH N/A
- Revenue Growth
- KAVL N/A
- AWH N/A
- 52 Week Low
- KAVL $0.58
- AWH $0.38
- 52 Week High
- KAVL $9.69
- AWH $5.65
- Technical
- Relative Strength Index (RSI)
- KAVL 60.50
- AWH 23.50
- Support Level
- KAVL $0.95
- AWH $0.38
- Resistance Level
- KAVL $1.22
- AWH $0.58
- Average True Range (ATR)
- KAVL 0.20
- AWH 0.07
- MACD
- KAVL 0.02
- AWH -0.02
- Stochastic Oscillator
- KAVL 51.76
- AWH 15.24
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.